Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.53
+0.07000.45%
Post-market: 15.52-0.0100-0.06%19:30 EDT
Volume:567.53K
Turnover:8.84M
Market Cap:999.43M
PE:-4.48
High:15.95
Open:15.41
Low:15.24
Close:15.46
52wk High:23.19
52wk Low:6.73
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.11
PE(LYR):-4.17

Loading ...

Analysts’ Top Healthcare Picks: Cullinan Management (CGEM), Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 08

Cullinan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Benzinga Earnings
·
May 07

Cullinan Therapeutics Q1 net loss widens

Reuters
·
May 07

BRIEF-Cullinan Therapeutics Q1 Operating Expenses USD 53.697 Million

Reuters
·
May 07

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 07

Cullinan CSO Jennifer Michaelson disposes 8,000 shares for $117,916

Reuters
·
May 07

Cullinan jumps after UCB acquires Candid Therapeutics

TIPRANKS
·
May 04

Cullinan Therapeutics Price Target Maintained With a $38.00/Share by BTIG

Dow Jones
·
May 04

Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 29

Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright

TIPRANKS
·
Apr 29

Cullinan Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $27 From $26

THOMSON REUTERS
·
Apr 29

BRIEF-Cullinan Therapeutics Inc Files For Mixed Shelf Offering

Reuters
·
Apr 28

Cullinan Therapeutics Inc: Files for Mixed Shelf Offering - SEC Filing

THOMSON REUTERS
·
Apr 28

Cullinan Therapeutics Inc: Sales Agreement Prospectus Covers Offering of up to $200 Mln of Common Stock

THOMSON REUTERS
·
Apr 28

FDA accepts Cullinan partner zipalertinib NDA for EGFR exon 20 NSCLC

Reuters
·
Apr 28

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations

THOMSON REUTERS
·
Apr 28

Cullinan Therapeutics Inc - Prescription Drug User Fee Act (Pdufa) Target Action Date Is February 27, 2027

THOMSON REUTERS
·
Apr 28

Cullinan Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 28